| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments |
|
Medicine details |
|
| Medicine name | selinexor (Nexpovio®) |
| Formulation | oral |
| Reference number | 4492 |
| Indication | In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy |
| Company | Karyopharm Therapeutics |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/05/2021 |
| NICE guidance | |